Diagnosis and Management of Cirrhosis-Related Osteoporosis

Lívia Alves Amaral Santos1, Fernando Gomes Romeiro1

  • 1Department of Internal Medicine, Botucatu Medical School, Universidade Estadual Paulista (UNESP), Av. Prof. Mário Rubens Guimarães Montenegro, s/n, Distrito de Rubião Jr., 18 608 917 Botucatu, SP, Brazil.

Insights

Cirrhosis patients often develop osteoporosis, a complication that persists even after liver transplantation due to immunosuppressants. This review details osteoporosis in cirrhosis, covering risk factors, diagnosis, and treatments.

Area of Science:

  • Hepatology
  • Endocrinology
  • Bone Metabolism

Background:

  • Cirrhosis management has improved, yet non-liver complications like osteoporosis are often overlooked.
  • Osteoporosis is a persistent complication post-liver transplantation, exacerbated by immunosuppressive therapy.

Purpose of the Study:

  • To analyze bone conditions in cirrhotic patients, focusing on osteoporosis.
  • To discuss risk factors, pathophysiology, diagnosis, screening, and treatment of osteoporosis in cirrhosis.

Main Methods:

  • Review of definitions for bone conditions in cirrhotic patients.
  • Analysis of risk factors, pathophysiology, diagnosis, screening, and treatment strategies.
  • Presentation of data on osteoporosis in cirrhosis and specific therapies.

Main Results:

  • Osteoporosis is a significant and often unresolved complication of cirrhosis.
  • Bone loss can worsen post-liver transplantation due to immunosuppressants.
  • Specific therapeutic approaches for osteoporosis in cirrhosis and post-transplant are discussed.

Conclusions:

  • Osteoporosis requires dedicated attention in cirrhosis management.
  • Effective screening and treatment strategies are crucial for improving patient outcomes.
  • Further research into managing bone health in liver transplant recipients is warranted.

Related Concept Videos

Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
4.5K
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
452
Bone Disorders01:29

Bone Disorders

Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
5.8K
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
565
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
601
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
307